| Literature DB >> 8617583 |
L C Hartmann1, M M Ames, J M Reid, R L Richardson.
Abstract
Diaziquone (AZQ) is a lipid soluble alkylating agent which was designed for increased CNS penetration. Its principle toxicity is myelosuppression. We conducted a phase I trial using AZQ in combination with GM-CSF to determine if the maximal tolerate dose (MTD) of AZQ could be escalated. Using GM-CSF on a standard schedule, we were unable to escalate the previously determined MTD of diaziquone with the use of this colony stimulating factor.Entities:
Mesh：
Substances：
Year: 1995 PMID： 8617583 DOI： 10.1007/bf00872869
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850